China Narrowly Trails US by 100 Days in AI Model Efficiency Race

Entrepreneurs and investors within the technology sector are driving an intensifying competition that places China at the forefront globally in delivering artificial intelligence applications to everyday users.

Despite this operational lead, Chinese companies are encountering increasing warnings about inflated market valuations, while the technical gap between the Chinese and American giants continues to narrow rapidly and consistently.

Analysis of the digital landscape reveals that China's field advantage does not stem from technological breakthroughs in laboratories but rather from effectively transferring AI from narrow research scopes to simple, low-cost daily applications, positioning China closer to the general user base.

International alerts regarding inflated financial valuations reflect expert concerns about a potential "investment bubble," fueled by aggressive stock purchases and speculation that have pushed Chinese companies' market values to record levels exceeding their current tangible profits.

China's 100-Day Competitive Gap with the US

At the 2026 Hong Kong Future Technology Stock Exchange Summit held in Shenzhen, Qi Chang, General Manager of Finance at Alibaba's Jeron Cloud Computing Group, stated that China lags behind the United States in computing power but trails by only 100 days in the efficiency of leading AI models.

Chang highlighted that China's major advantage lies in applications, supported by a vast pool of engineers, investors, and the current nature of its economic development, according to the "scmp" website.

Recent developments show Chinese laboratories releasing commercial and open-source AI models whose efficiency closely approaches that of American counterparts such as OpenAI and Anthropic. Furthermore, the lower operational costs have led some American companies to utilize Chinese providers like DeepSeek.

China's Growing Influence in Global Pharmaceutical Industry

Reflecting rapid shifts in the global pharmaceutical sector, China's rise in developing cancer treatments has drawn attention during the annual meeting of the American Society of Clinical Oncology held this week in Chicago. This has raised growing concerns within the United States about its declining influence in the biotechnology field.

Market Peak and Early Investment Concerns

Conversely, Tai Tong, partner at Matrix Partners China, warned that AI funding rounds in the country may be nearing the peak of a bullish market, describing companies as "very expensive," which is prompting his firm to seek early-stage investment opportunities.

This perspective aligns with that of Luo Xiniu, Vice President of Technology, Media, and Telecommunications in the investment banking division at China International Capital Corporation, who noted that AI stocks have reached unprecedented high levels. He also affirmed that Chinese solutions will inevitably surpass others in scale and dissemination in the future.